Purpose of the development: Antifungal drug.

Recommended application field: Medicine, pharmacology, veterinary science, beekeeping, textile industry.

Advantages over analogues: The release of the drug in Ukraine will make it possible to refuse imports of analogues from other countries, to use it more widely in various sectors (medicine, veterinary medicine, beekeeping, textile industry, etc.), export the drug to the CIS countries and foreign countries.

The development stage readiness: tested in laboratory condition

Description of the development:
()
An antifungal drug of a new generation (based on BIFAZOL) has been created. BIFAZOLATE differs from the previous algae (up to 2%, which corresponds to the necessary therapeutic doses of BIFAZOLATE). The drug was successfully tested in animals and volunteers and showed high effectiveness in the treatment of fungal skin diseases, including candidomycosis. The technology for obtaining BIFAZOLATE is almost in all respects similar to the BIFAZOLE synthesis technology, but shorter by one stage. We can assume that the new drug will be cheaper than BIFAZOL). The development is protected by the patent of Ukraine for invention.

Information about newness of the development:
there are Ukrainian patents -- 2 items

corresponds technical description
Guarantees stable results getting

Possibility of transfer abroad:
Combinated reduction to industrial level
Creation of joint enterprise

Photo

Country Ukraine

For additional information turn to:
E-mail: gal@uintei.kiev.ua